IHEEZO

Reimbursement

IHEEZO is the only FDA-approved topical ocular anesthetic with a permanent J-code and transitional pass through status.

This allows for separate payment for Medicare Fee-for-Service patients in the ASC/HOPD setting and in the physician office setting.

Reimbursement Guide

Ordering

IHEEZO may be ordered from any of the following wholesalers/distributors.

Ordering and reimbursement are supported by a dedicated Reimbursement Business Manager through our Harrow Cares program (see more information below).

Need help with insurance and out-of-pocket costs?

Access Made Easy

One-stop support for you, your staff, and your patients

Personalized Access Support

Connect with a specialist in under 30 seconds for access and cost support. Track patients support updates in real-time via the Provider Portal.

Seamless Enrollment & Coverage

Offers simplified enrollment for benefit investigation and coverage verification. Get alerts when a PA is required, or proceed directly—order, treat, and submit for reimbursement.

Copay & Product Assurance

Enroll in our commercial copay program, foundation research, or patient assistance based on need. Receive product replacement for breakage, spoilage, or loss—when you treat, you’re covered.**

**Subject to program terms and limitations. Please contact 1-866-HROWINC (476-9462) for additional details.

Commercial

Copay Program

Available to commercially insured patients. Excludes Medicaid, Medicare, Tricare, etc.
Pay as little as $0
Program Maximum Annual Benefit: $5,000
Program Enrollment Period: Start Date through December 31 of that calendar year
Once enrolled, a claim should be submitted within 180 days of the treatment date
Treatments within the last 120 days may qualify for retroactive copay assistance. Enroll immediately with an Enrollment Form and insurer EOB.

Important Safety Information

IHEEZO is contraindicated in patients with a history of hypersensitivity to any component of this preparation.

IHEEZO should not be injected or intraocularly administered.

Patients should not touch the eye for at least 10 to 20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye.

Prolonged use of a topical ocular anesthetic may produce permanent corneal opacification and ulceration with accompanying visual loss.

Do not touch the dropper tip to any surface as this may contaminate the gel.

IHEEZO is indicated for administration under the direct supervision of a healthcare provider. IHEEZO is not intended for patient self-administration.

The most common adverse reactions in studies following IHEEZO administration (incidence greater than or equal to 5%) were mydriasis, conjunctival hyperemia, and eye irritation.

You are encouraged to report suspected adverse reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

For additional information about IHEEZO, please see the full Prescribing Information.